A Phase 2, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
Latest Information Update: 01 Dec 2022
At a glance
- Drugs Bevacizumab (Primary) ; Efineptakin alfa (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Genexine
- 25 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 16 Sep 2021 New trial record